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Changes in brain structure and cognitive decline occur in Chronic Obstructive Pulmonary
Disease (COPD). They also occur with smoking and coronary artery disease (CAD), but it is
unclear whether a common mechanism is responsible.
Methods
Brain MRI markers of brain structure were tested for association with disease markers in
other organs. Where possible, principal component analysis (PCA) was used to group mark-
ers within organ systems into composite markers. Univariate relationships between brain
structure and the disease markers were explored using hierarchical regression and then
entered into multivariable regression models.
Results
100 participants were studied (53 COPD, 47 CAD). PCA identified two brain components:
brain tissue volumes and white matter microstructure, and six components from other organ
systems: respiratory function, plasma lipids, blood pressure, glucose dysregulation, retinal
vessel calibre and retinal vessel tortuosity. Several markers could not be grouped into com-
ponents and were analysed as single variables, these included brain white matter hyperin-
tense lesion (WMH) volume. Multivariable regression models showed that less well
organised white matter microstructure was associated with lower respiratory function (p =
0.028); WMH volume was associated with higher blood pressure (p = 0.036) and higher C-
Reactive Protein (p = 0.011) and lower brain tissue volume was associated with lower cere-
bral blood flow (p<0.001) and higher blood pressure (p = 0.001). Smoking history was not an
independent correlate of any brain marker.
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Conclusions
Measures of brain structure were associated with a range of markers of disease, some of
which appeared to be common to both COPD and CAD. No single common pathway was
identified, but the findings suggest that brain changes associated with smoking-related dis-
eases may be due to vascular, respiratory, and inflammatory changes.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) and coronary artery disease (CAD) are both
associated with cognitive impairment and changes to brain structure [1–3], but the mecha-
nisms have not been identified. Smoking, and cigarette smokers have an elevated risk of cogni-
tive decline, cerebrovascular disease and dementia [4, 5]. Meta-analyses have shown that
current smoking increases the risk of Alzheimer’s disease and vascular dementia compared to
never smoking [5]. Relationships have also been found between greater pack year smoking his-
tory and greater rate of cognitive decline [6].
COPD and CAD frequently co-occur and, when combined, are associated with worse prog-
nosis than either disease in isolation [7]. The two diseases are also linked. Cardiovascular dis-
ease increases the risk of exacerbations [8] and is a major cause of mortality in COPD [9].
COPD increases the risk of angina, myocardial infarction, hospitalisation and cardiovascular
mortality [10, 11], with patients being particularly vulnerable to acute vascular events during
the peri-exacerbation period [12]. The two diseases also share a number of risk factors includ-
ing smoking, ageing, sedentary lifestyle and exposure to air pollution, although these risk fac-
tors do not fully explain their co-occurrence [13].
Magnetic resonance imaging (MRI) studies show that smoking is associated with progres-
sion of white matter hyperintense lesions (WMHs) of presumed vascular origin [14] and both
total and localised reduction in grey matter volume [15, 16]. Diffusion tensor imaging (DTI)
studies suggest that microstructural abnormalities also occur [17, 18]. The pathophysiological
mechanisms responsible for these changes are unclear. For example, whether all the damage is
due to direct effects of smoking, or specific effects of pulmonary and cardiovascular disease, or
mechanisms common to both. Furthermore, smoking may interact with other risk factors
associated with accelerated age-related brain changes and cognitive decline, including lifestyle,
psychosocial factors and co-morbid disease. This analysis was designed to test whether there
are common factors contributing to brain changes in COPD and CAD.
Materials and methods
Participants
This prospectively planned cross-sectional analysis combined data from two complementary
studies that used identical assessment methods to permit combination. 736 patients were
assessed for eligibility and 103 enrolled into one of the two studies. Three patients did not have
MRI, so were excluded from this analysis. This cohort comprised 53 patients with a primary
diagnosis of COPD who had experienced at least one exacerbation in the preceding year and
47 patients with a primary diagnosis of CAD, 23 of whom also had COPD. They were recruited
from outpatient respiratory and cardiology departments at St George’s Hospital NHS Founda-
tion Trust between December 2015 and October 2017. They were included if they were aged
over 40 years and had at least 10 pack years smoking history. COPD was defined using GOLD
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criteria. CAD patients were included if they had a Gensini score for coronary atherosclerosis
greater than zero (i.e. indicative of coronary artery narrowing) [19]. Exclusion criteria
included a primary respiratory diagnosis other than COPD, an exacerbation within the previ-
ous six weeks, obstructive sleep apnoea, need for home ventilation, cerebrovascular, neurologi-
cal or uncontrolled major psychiatric disorder, current alcohol or drug abuse, uncontrolled
hypertension, vascular complications of diabetes, hepatic failure, end-stage renal disease, non-
cured tumours with prognosis of less than one year, or contraindications for MRI.
Ethical approval was granted by the national research ethics committee London–Dulwich
(16/LO/0547) and East Midlands–Leicester South Research Ethics Committee (15/EM/0425).
All patients provided informed written consent to participate in this study.
Clinical and imaging markers
Standard demographic information (age and sex) was collected together with medical history,
smoking status and measures representing:
Respiratory function. Post-bronchodilator spirometry (Forced Expiratory Volume in 1
second [FEV1] and Forced Vital Capacity [FVC]) performed using ATS/ERS criteria, arterial
oxygen saturation and MRC dyspnoea score.
Vascular risk. Pack year smoking history, diastolic and systolic blood pressure, total cho-
lesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), non-HDL cholesterol
(i.e., total cholesterol–HDL), body mass index (BMI), glycated haemoglobin (HbA1C),
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).
Cardiovascular system markers. Aortic pulse wave velocity assessed using the Vicor-
der1 Arterial Stiffness Model (SMT medical GmbH & Co., Wuerzburg, Germany), serum
troponin T and cerebral perfusion (median and peak height of grey matter cerebral blood flow
[CBF]) quantified from brain MRI.
Systemic inflammation. High-sensitivity C-Reactive Protein (hs-CRP), fibrinogen and
total neutrophil count.
Microvascular pathology. Quantitative markers of retinal microvascular morphometry
including arteriole calibre, venule calibre, arteriole branching angle, venule branching angle,
arteriole tortuosity, venule tortuosity and total fractal dimension, as well as urine albumin to
creatinine ratio (ACR), a marker of renal microvascular disease.
Brain MRI measures. Markers of brain macrostructure (white matter, grey matter, cere-
brospinal fluid [CSF], and lateral ventricle volumes), white matter hyperintense lesions
(WMHs), and markers of white matter microstructure (median and peak height of white mat-
ter fractional anisotropy [FA] and mean diffusivity [MD]).
All measures were acquired during a single visit. Full details of data acquisition and analysis
methods for retinal fundus photography and MRI scans are given in S1 Appendix.
Statistical analysis
Preliminary data analysis. To control for possible confounding effects of age and sex all
analyses were performed on the covariate adjusted estimates after correcting for these vari-
ables. Several variables had a non-Gaussian distribution and were transformed to approximate
Guassianity using log10 and square root transformations with or without first reflecting about
the mean. Pairwise deletion was used for cases with missing data.
Principal Component Analysis (PCA) was used to aggregate appropriate continuous mark-
ers into composite measures. Direct oblimin rotation was performed using SPSS (IBM SPSS
Statistics 24). Six composite measures were derived from the markers for vascular risk, respira-
tory function, cardiovascular system, retinal microvascular pathology and systemic
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inflammation. A similar approach was used to combine the measures of brain structure. Indi-
vidual variables with less than 0.5 Kaiser-Meyer-Olkin sampling adequacy were removed from
the model and the PCA re-calculated. Scree tests (above the ‘elbow’ in the eigenvalue scree
plot) were used to determine the number of components to extract. Component scores were
computed using least squares regression which took into account each marker’s contribution
to the component, the correlations between markers and correlations between components
[20]. For markers that did not load onto a component, the measured values (after age and sex
adjustment) were used. For clarity, the following naming conventions are used: composite
measure names given in Title Case; single marker names given in italics.
Relationships between disease markers. Pearson’s correlations were performed to inves-
tigate univariate relationships between brain structure and markers from other organs and
these were summarised in a network diagram generated using Cytoscape (version 3.7.2 https://
cytoscape.org/).
A three-step hierarchical regression was then used to test the correlation of each disease
marker with each brain measure. Step 1 was a simple correlation with data from both diagnos-
tic groups combined. If there was a significant correlation (p<0.05), Step 2 was a test of the
effect of including diagnostic group membership. Step 3 tested whether the slope of the rela-
tionship was significantly different between the two diseases by inclusion of a diagnostic
group-by-disease marker interaction term. Markers that showed a significant correlation with
changes in the brain in these univariate analyses, but no difference in slope between the two
diseases, were then entered into multivariable linear models.
Results
Demographics
Cohort demographics are given in Table 1. The mean age was 68 years, 22% were current
smokers. Of those with COPD, the median FEV1% predicted was 74 (interquartile range
[IQR] 54–92). Hypertension was present in 83%, 5% had type-2 diabetes and 77% had dyslipi-
daemia. The median Gensini score in patients with CAD was 22 (IQR 13–46). All participants
reported some degree of breathlessness (MRC dyspnoea�1).
Principal component analysis
Naming and interpretation of components was based on marker variables with high compo-
nent loadings (>0.6). Markers loaded positively onto a component unless stated otherwise.
Respiratory function. One component was extracted (Respiratory Function) which
explained 75.4% of the total variance. It contained FEV1% predicted, FVC % predicted and
SaO2. MRC dyspnoea was retained as a separate variable to provide a measure of respiratory
symptoms (see S1 Table in S2 Appendix).
Vascular risk. Three components were extracted from the vascular risk factors: Plasma
Lipids, comprising Non-HDL (negative loading) and HDL; Blood Pressure comprising systolic
blood pressure and diastolic blood pressure; Glucose Dysregulation comprising HbA1C,
HOMA-IR and BMI. These explained 71.4% of the total variance of the model (Glucose Dysre-
gulation = 33.8%, Blood Pressure 23.1%, Plasma Lipids 14.6%) (see S2 Table in S2 Appendix).
Pack years did not fit any component so was retained as a separate variable.
Cardiovascular system. These markers did not form a single composite measure, so were
analysed as individual markers.
Systemic inflammation. These markers did not form a single composite measure so were
analysed as individual markers.
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Table 1. Demographics and clinical characteristics.
Demographics CAD (n = 47) COPD (n = 53) Whole cohort (n = 100)
Age (years) 68 ± 7 69 ± 8 68 ± 8
Males (%) 77 62 69
Current smokers (%) 13 30 22
Respiratory function and symptoms
FEV1% predicted 89 [73–96] 55 [32–77] 74 [54–92]
FVC % predicted 97 ± 19 82 ± 24 89 ± 23
FEV1/FVC 0.73 [0.67–0.77] 0.56 [0.39–0.62] 0.65 [0.51–0.73]
Oxygen saturations (%) 97 [96–97] 96 [94–97] 96 [95–97]
MRC dyspnoea 2 [1–2] 3 [2–4] 2 [2–4]
Vascular risk factors
Pack years smoking history 30 [19–45] 45 [27–56] 40 [20–50]
Systolic blood pressure (mm Hg) 140 ± 17 150 ± 16 145 ± 17
Diastolic blood pressure (mm Hg) 73 ± 7 75 ± 10 74 ± 9
Total cholesterol (mmol/L) 5.1 ± 1.2 4.9 ± 1.1 5.0 ± 1.3
HDL (mmol/L) 1.3 [1.0–1.5] 1.6 [1.3–2.3] 1.4 [1.2–1.8]
LDL (mmol/L) 3.0 ± 1.1 2.5 ± 1.1 2.8 ± 1.1
Non-HDL (mmol/L) 3.8 ± 1.1 3.1 ± 1.2 3.4 ± 1.2
Body mass index (kg/m2) 28 [26–31] 27 [24–31] 28.0 [24.2–31.0]
HbA1c (mmol/mol) 38 [36–42] 37 [35–41] 38 [35–41]
HOMA-IR 1.23 [0.78–1.84] 1.19 [0.76–1.88] 1.21 [0.79–1.87]
Cardiovascular function
Aortic pulse wave velocity (m/s) 9.8 [8.7–11.3] 9.9 [9.0–11.2] 9.9 [8.8–11.3]
Troponin T (ng/L) 8.5 [6.8–13.0] 2.8 [2.2–4.1] 4.2 [2.7–8.0]
Median CBF (mL/100g/min) 37.2 ± 8.2 41.5 ± 7.4 39.5 ± 0.8
CBF peak height 0.045 ± 0.001 0.041 ± 0.076 0.043 ± 0.009
Systemic inflammation
Hs-CRP (mg/L) 2.4 [1.0–5.7] 3.4 [1.6–6.3] 3.3 [1.2–6.0]
Fibrinogen (g/L) 3.3 [2.9–3.7] 3.7 [3.0–4.4] 3.5 [3.0–4.0]
Neutrophil count x109/L 4.5 [3.5–5.7] 3.3 [3.5–5.7] 4.5 [3.5–5.7]
Microvasculature
Arteriole calibre (CRAE zone C, μm) 147.2 ± 13.1 138.8 ± 14.7 146.9 ± 13.0
Venule calibre (CRVE zone C, μm) 213.5 ± 23.1 208.4 ± 25.9 210.8 ± 22.6
Arteriole tortuosity 1.10 [1.09–1.12] 1.10 [1.09–1.12] 1.10 [1.09–1.12]
Venule tortuosity 1.10 [1.09–1.12] 1.10 [1.09–1.12] 1.10 [1.09–1.12]
Arteriole branching angle (˚) 73.5 [64.7–82.6] 77.9 [67.1–82.7] 75.2 [66.8–83.0]
Venule branching angle (˚) 74.1 ± 10.2 77.0 ± 11.5 75.4 ± 10.8
Total fractal dimension 0.03 [0.02–0.05] 0.03 [0.02–0.05] 0.03 [0.02–0.05]
Urine ACR 2.2 [0.8–3.6] 1.3 [0.0–3.1] 1.5 [0.4–3.2]
Brain structure
Grey matter volume (% TIV) 40.0 ± 3.0 40.1 ± 3.5 40.0 ± 3.3
White matter volume (% TIV) 28.1 ± 2.7 27.9 ± 2.6 28.0 ± 2.7
CSF volume (% TIV) 31.9 ± 5.0 32.0 ± 5.2 32.0 ± 5.1
Lateral ventricle volume (% TIV) 3.09 [2.41–4.13] 3.24 [2.55–4.31] 3.21 [2.53–4.28]
WMH volume (% TIV) 0.27 [0.11–0.78] 0.36 [0.17–1.26] 0.32 [0.14–0.82]
Median FA 0.41 ± 0.02 0.39 ± 0.03 0.40 ± 0.03
FA peak height 0.026 ± 0.002 0.029 ± 0.002 0.028 ± 0.002
Median MD (×10-3mm2 s-1) 0.72 ± 0.03 0.75 ± 0.03 0.74 ± 0.03
(Continued)
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Retinal microvascular pathology. Retinal microvascular data was unavailable for 16
patients due to ungradable retinal images. Two components were extracted: Retinal Vessel
Calibre, comprising arteriole calibre and venule calibre and Retinal Vessel Tortuosity, com-
prising arteriole tortuosity, venule tortuosity and total fractal dimension (negative loading).
These explained 56.0% of the total variance of the model (Retinal Vessel Calibre 29.5%, Retinal
Vessel Tortuosity 26.5%). Both were used for the tests of association with brain structure (see
S3 Table in S2 Appendix). Arteriole branching angle did not fit any component and was not
considered further.
Brain structure. Two principal components were extracted. One was Brain Tissue Vol-
ume, composed of grey matter volume (which had negative loading) and CSF and lateral ven-
tricle volumes that had positive loadings. The other was White Matter Microstructure
composed of FA peak height, median FA (both with negative loading), and median MD with a
positive loading. Together, these components explained 80.5% of the total variance of the
model (White Matter Microstructure 48.6%, Brain Tissue Volume 31.9%). An initial PCA
found that WMH volume loaded approximately equally onto both brain components, so it
was removed from the PCA and analysed as a separate brain variable (see S4 Table in S2
Appendix).
Single variables. The following disease markers were analysed as single variables: MRC
dyspnoea, pack years smoking, troponin T, aortic pulse wave velocity, median CBF, CBF peak
height, urine ACR, hs-CRP, fibrinogen and neutrophil count.
Correlation analysis
Association between disease markers outside of the brain. Significant correlations
between the different disease markers were infrequent and, where present, were generally
weak (|r| = 0.21 to 0.42). Several relationships with Plasma Lipids were the reverse of what was
expected and probably because lipid lowering treatment was given to patients with high serum
cholesterol (see S5 Table in S2 Appendix). Of note, a significant correlation was found between
higher urine ACR and lower median CBF (r = 0.273, p = 0.027).
Univariate association between brain structure and disease markers. A number of cor-
relations were found between markers of brain structure and disease markers in other organs.
This is summarised in a network diagram (Fig 1A). The subnetworks show the specific mark-
ers that were correlated with Brain Tissue Volume (Fig 1B), WMH Volume (Fig 1C) and
White Matter Microstructure (Fig 1D). It will be noted that retinal markers did not correlate
with any brain measures.
The relationship between Brain Tissue Volume and the disease markers was explored
using hierarchical regression (full details in S6 Table in S2 Appendix), the significant
Table 1. (Continued)
Demographics CAD (n = 47) COPD (n = 53) Whole cohort (n = 100)
MD peak height 0.14 ± 0.02 1.14 ± 0.02 0.14 ± 0.02
Demographic and clinical characteristics. For data with a Gaussian distribution across the whole cohort, means ± standard deviations are presented, for frequency data
percentages are presented and for non-Gaussian data medians and upper and lower quartiles [Q1-Q3] are presented. Median and normalised peak heights for the
distribution of MD and FA values within the normal appearing white matter are reported. ACR = Albumin to Creatinine Ratio, CBF = Cerebral Blood Flow,
COPD = Chronic Obstructive Pulmonary Disease, CRAE = Central Retinal Artery Equivalent, CRVE = Central Retinal Vein Equivalent, CSF = Cerebrospinal Fluid,
FA = Fractional Anisotropy, FEV1 = Forced Expiratory Volume in 1 second, FVC = Forced Vital Capacity, HbA1c = Glycated Haemoglobin, HDL = High-Density
Lipoprotein, HOMA-IR = Homeostatic Model Assessment of Insulin Resistance, Hs-CRP = high-sensitivity C-Reactive Protein, LDL = Low-Density Lipoprotein,
MD = Mean Diffusivity, MRC = Medical Research Council, TIV = Total Intracranial Volume, WMH = White matter hyperintense lesion.
https://doi.org/10.1371/journal.pone.0259375.t001
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relationships are shown in Table 2. This component was significantly associated with median
CBF, Blood Pressure and CBF peak height, such that higher component scores (greater CSF
volume and lower grey matter volume) were associated with lower median CBF, higher blood
pressure and higher CBF peak height. In each of the comparisons there was no significant dif-
ference between the two diagnostic groups. Similarly, there was no difference in slope of the
relationships between diagnostic groups, as shown at Step 3.
Higher WMH volume was significantly associated with lower Respiratory Function, and
higher MRC dyspnoea, pack years, Blood Pressure, troponin T, fibrinogen and hs-CRP; full
details of all analyses are presented in S7 Table in S2 Appendix, and significant relationships
are shown in Table 3. Respiratory Function, MRC dyspnoea, Blood Pressure, troponin T, and
hs-CRP showed no significant effect of disease group.
Fig 1. Network diagram. Pearson’s correlations between non-brain and brain measures (circles) are represented as network connections. All lines indicate significance
at p<0.05, line thickness indicates strength of correlation (correlation coefficient). (A) whole network. (B) Brain Tissue Volume (green), (C) white matter hyperintensity
volume (blue), (D) White Matter Microstructure (orange). Dark colours show direct correlations with a brain measure. Light colours indicate intercorrelations between
non-brain measures. Circle size reflects the number of connections. Relationships with CBF peak height and Plasma Lipids are not shown. ACR = Urine Albumin to
Creatinine Ratio, BTV = Brain Tissue Volume, BP = Blood Pressure, CBF = median cerebral blood flow, CRP = high-sensitivity C-Reactive Protein, Fibr = Fibrinogen,
Glu = Glucose Dysregulation, Micro = Lower White Matter Microstructure, MRC = MRC dyspnoea, Neut = Neutrophils, PckYr = pack year smoking history,
Resp = Respiratory Function, rCal = Retinal Vessel Calibre, rTor = Retinal Vessel Tortuosity, Trop = troponin T, WMH = white matter hyperintense lesion volume.
https://doi.org/10.1371/journal.pone.0259375.g001
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Table 2. Single variable models (hierarchical linear regression)–Brain Tissue Volume.
Predictor Main Effect (Disease
marker)




Step t p t p t p adj. r2 F p
Blood Pressure† 1 4.133 <0.001 0.153 17.082 <0.001
2 4.399 <0.001 -1.440 0.153 0.163 9.682 <0.001
3 2.078 0.041 -1.344 0.182 0.534 0.595 0.156 6.497 0.001
Median CBF 1 -4.795 <0.001 0.191 22.989 <0.001
2 -4.827 <0.001 0.834 0.406 0.189 11.804 <0.001
3 -3.507 0.001 0.840 0.403 -0.278 0.782 0.180 7.816 <0.001
CBF peak height 1 3.736 <0.001 0.122 13.961 <0.001
2 3.725 <0.001 0.549 0.584 0.116 7.078 0.001
3 2.483 0.015 0.545 0.587 0.338 0.736 0.107 4.711 0.004
Three-step hierarchical linear model showing the relationship between Brain Tissue Volume and disease markers. Step 1 predictors: disease marker only; Step 2
predictors: disease marker and diagnostic group (Group); Step 3 predictors: disease marker, diagnostic group, diagnostic group × disease marker interaction. Reported
are the t-statistics (t) and p-values for each main effect and interaction, as well as the regression coefficient (r2), adjusted regression coefficient (adj r2), F-statistics (F)
and p-values (p) for the overall models. The COPD>CAD contrast for the main effect of group and the group × disease marker interaction is shown. All models
included a constant term (not shown). All variables were adjusted for age and sex. CBF = Cerebral Blood Flow.
†Principal component.
https://doi.org/10.1371/journal.pone.0259375.t002
Table 3. Single variable models (hierarchical linear regression)–WMH volume.
Predictor Main Effect (Disease
marker)
Main Effect (Group) Interaction
(Group × Disease marker)
Overall model
Step t P t p t p adj. r2 F p
Respiratory Function† 1 -2.559 0.012 0.052 6.550 0.012
2 -2.501 0.014 -0.616 0.539 0.048 3.444 0.036
3 -1.466 0.146 -0.676 0.501 0.292 0.771 0.039 2.302 0.082
MRC dyspnoea 1 2.430 0.017 0.048 5.906 0.017
2 2.345 0.021 -0.714 0.477 0.043 3.193 0.045
3 0.596 0.533 -0.413 0.681 0.588 0.558 0.036 2.230 0.090
Pack years (square root) 1 1.985 0.050 0.029 3.939 0.050
2 1.787 0.077 0.396 0.693 0.021 2.031 0.137
3 1.042 0.300 0.398 0.691 0.069 0.945 0.010 1.342 0.266
Blood Pressure† 1 3.034 0.003 0.084 9.206 0.003
2 2.830 0.006 0.137 0.892 0.074 4.561 0.013
3 2.144 0.035 0.045 0.965 -0.640 0.524 0.068 3.157 0.029
Troponin T (log10) 1 2.443 0.017 0.052 5.967 0.017
2 2.066 0.042 0.522 0.603 0.044 3.096 0.050
3 2.197 0.031 0.230 0.819 -1.291 0.200 0.052 2.635 0.055
Hs-CRP (log10) 1 3.125 0.002 0.084 9.765 0.002
2 3.082 0.003 0.885 0.378 0.082 5.263 0.007
3 2.840 0.006 0.888 0.377 -0.980 0.330 0.081 3.827 0.012
Three-step hierarchical linear model showing the relationship between WMH volume and disease markers. Step 1 predictors: disease marker only; Step 2 predictors:
disease marker, group; Step 3 predictors: disease marker, diagnostic group (Group), diagnostic group × disease marker interaction. Reported are the t-statistics (t) and
p-values for each main effect and interaction, as well as the regression coefficient (r2), adjusted regression coefficient (adj r2), F-statistics (F) and p-values (p) for the
overall models. The COPD>CAD contrast for the main effect of group and the group × disease marker interaction is shown. All models included a constant term (not
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The models for White Matter Microstructure showed that less well organised structure
was associated with lower Respiratory Function and higher MRC dyspnoea score, Blood Pres-
sure, troponin T and hs-CRP. The full results can be found in S8 Table in S2 Appendix and sig-
nificant relationships are shown in Table 4. There was a consistent significant effect of group
membership at Step 2; COPD patients having on average less well organised white matter than
CAD patients. Disease markers that still retained a significant effect of the disease marker after
inclusion of the disease group effect were carried through to the multivariable model.
Multi-variable associations between brain structure and disease markers
The effect of Median CBF and CBF peak height on Brain Tissue Volume was found to be collin-
ear, so only Blood Pressure and median CBF, were included as predictors in the multivariable
model. Both were independent predictors: median CBF (t = -3.592, p<0.001) and Blood Pres-
sure (t = 3.356, p = 0.001), Table 5. The model explained 30% of the total variance in Brain Tis-
sue Volume, adjusted r2 = 0.279, p<0.001. Scatterplots showing the univariate relationship
between Brain Tissue Volume and these markers are shown in Fig 2A.
The multivariable model of WMH volume contained Respiratory Function, MRC dyspnoea,
Blood Pressure, troponin T, and hs-CRP explained 22% of the total variance (adjusted r2 =
0.165, p = 0.002). Blood Pressure (t = 2.129. p = 0.036) and hs-CRP (t = 2.619. p = 0.011)
remained as significant independent predictors (Table 5). Scatterplots showing the relation-
ship between WMH volume and Blood Pressure and hs-CRP are shown in Fig 2B.
Table 4. Single variable models (hierarchical linear regression)–White Matter Microstructure.
Predictor Main Effect (Disease
marker)




Step t P t p t p adj. r2 F p
Respiratory Function† 1 -6.335 <0.001 0.287 40.126 <0.001
2 -4.133 <0.001 2.855 0.005 0.337 25.634 <0.001
3 -1.797 0.076 2.757 0.007 -0.234 0.816 0.330 16.938 <0.001
MRC dyspnoea 1 5.084 <0.001 0.202 25.847 <0.001
2 2.290 0.024 2.999 0.003 0.263 18.484 <0.001
3 2.138 0.035 2.266 0.026 -1.188 0.238 0.266 12.846 <0.001
Blood Pressure† 1 3.984 <0.001 0.143 15.875 <0.001
2 2.895 0.005 3.883 <0.001 0.261 16.745 <0.001
3 1.180 0.241 3.911 <0.001 0.582 0.562 0.256 11.191 <0.001
Troponin T (log10) 1 4.796 <0.001 0.196 23.01 <0.001
2 3.353 0.001 3.886 <0.001 0.306 20.876 <0.001
3 1.743 0.085 3.779 <0.001 0.039 0.969 0.298 13.760 <0.001
Hs-CRP (log10) 1 2.142 0.035 0.036 4.587 0.035
2 2.221 0.029 5.552 <0.001 0.266 18.428 <0.001
3 2.551 0.012 5.585 <0.001 -1.394 0.167 0.274 13.056 <0.001
Three-step hierarchical linear model showing the relationship between White Matter Microstructure and disease markers. Step 1 predictors: disease marker only; Step 2
predictors: disease marker, group (Group); Step 3 predictors: disease marker, group, group × disease marker interaction. Reported are the t-statistics (t) and p-values for
each main effect and interaction, as well as the regression coefficient (r2), adjusted regression coefficient (adj r2), F-statistics (F) and p-values (p) for the overall models.
The COPD>CAD contrast for the main effect of group and the group × disease marker interaction is shown. All models included a constant term (not shown). All
variables were adjusted for age and sex. Hs-CRP = high-sensitivity C-Reactive Protein, MRC = Medical Research Council.
†Principal component.
https://doi.org/10.1371/journal.pone.0259375.t004
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The multivariable model for White Matter Microstructure contained Respiratory Function,
MRC dyspnoea score, Blood Pressure, troponin T and hs-CRP and explained 45% of the vari-
ance (adjusted r2 = 0.402, p<0.001). Only Respiratory Function (t = -2.234, p = 0.028)
remained as significant independent predictor of White Matter Microstructure (Table 5),
although troponin T approached significance (p = 0.054). Scatterplots showing the relationship
between White Matter Microstructure and Respiratory Function, troponin T and are shown in
Fig 2C.
Discussion
This study was designed to test whether there were common factors linking COPD and CAD
to brain changes. A large number of correlations were found between brain MRI markers and
markers of disease in the respiratory, cardiovascular and inflammatory systems and the slope
of these relationships was not different between COPD and CAD. This suggests that there are
Table 5. Multivariable models of brain structure.
Brain Tissue Volume
Predictor B [95% Confidence Intervals] SE t p
Constant 0.005 [-0.178, 0.188] 0.092 0.057 0.955
Blood Pressure† 0.311 [0.127, 0.496] 0.093 3.356 0.001
Median CBF -0.048 [-0.073, -0.024] 0.012 -3.592 <0.001
r2 adj. r2 SE F p
Overall model 0.297 0.279 0.848 17.286 <0.001
WMH Volume
Predictor B [95% Confidence Intervals] SE t p
Constant -0.001 [-0.099, 0.097] 0.049 -0.030 0.977
Respiratory Function† -0.032 [-0.166, 0.102] 0.067 -0.473 0.637
MRC dyspnoea 0.019 [-0.084, 0.122] 0.052 0.366 0.715
Blood Pressure† 0.114 [0.007, 0.223] 0.054 2.129 0.036
Troponin T (log10) 0.187 [-0.209, 0.608] 0.205 0.971 0.335
Hs-CRP (log10) 0.247 [0.074, 0.546] 0.118 2.619 0.011
r2 adj. r2 SE F p
Overall model 0.216 0.165 0.448 4.246 0.002
White Matter Microstructure
Predictor B [95% Confidence Intervals] SE t p
Constant -0.213 [-0.513, 0.087] 0.151 -1.415 0.199
Group 0.397[-0.072, 0.865] 0.235 1.687 0.096
Respiratory Function† -0.262 [-0.495, -0.028] 0.117 -2.234 0.028
MRC dyspnoea 0.029 [-0.175, -0.233] 0.103 0.282 0.779
Blood Pressure† 0.164 [-0.027, 0.356] 0.096 1.710 0.091
Troponin T (log10) 0.694 [-0.012, 1.401] 0.355 1.958 0.054
Hs-CRP (log10) 0.366 [-0.047, 0.778] 0.207 1.765 0.082
r2 adj. r2 SE F P
Overall model 0.445 0.402 0.773 10.177 <0.001
Multiple linear regression results showing relationships between disease markers and measures of brain structure. Reported are the unstandardised beta coefficients (B),
their 95% confidence intervals and standard error estimates (SE), the t-statistics (t) and p-values for each main effect and the regression coefficient (r2), adjusted
regression coefficient (adj r2), SE, F-statistics (F) and p-values (p) for each overall model. All variables were adjusted for age and sex. CBF = Cerebral Blood Flow, Hs-
CRP = high-sensitivity C-Reactive Protein, MRC = Medical Research Council, WMH = White matter hyperintense lesion.
†Principal component.
https://doi.org/10.1371/journal.pone.0259375.t005
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common mechanisms linking these two diseases to changes in the brain. Multivariable models
showed that lower brain tissue volumes were significantly associated with higher blood pres-
sure and lower CBF as independent predictors. Greater WMH volume was associated with
higher blood pressure and higher hs-CRP. Less well organised white matter microstructure
was significantly associated with lower respiratory function and, possibly, serum troponin T. It
is noteworthy that the amount of previous smoking was not an independent predictor of any
brain marker when other factors were considered. It is not possible to evaluate the degree to
which smoking directly causes brain damage rather than through indirect effects on other
Fig 2. Relationships between brain structure and other disease markers. Plots showing the relationship between:
Brain Tissue Volume, median CBF and Blood Pressure (panel A); WMH volume, hs-CRP and Blood Pressure (panel
B); and White Matter Microstructure, Respiratory Function and troponin T (panel C) for COPD (green) and CAD
(blue) patients. The adjusted r2 goodness of fit is presented for the whole cohort. Data has been adjusted for age and
sex. CBF = cerebral blood flow, hs-CRP = high-sensitivity C-Reactive Protein, WMH = white matter hyperintense
lesion.
https://doi.org/10.1371/journal.pone.0259375.g002
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organs, however, no evidence was found of an independent effect of amount of smoking
beyond those related to markers of respiratory and cardiovascular disease. Although causality
cannot be determined in this cross-sectional study, the findings suggest the presence of pulmo-
nary, inflammatory and vascular aetiologies for brain changes in these patients with smoking-
related heart and lung disease.
The pathway between lung and brain changes is not clear, but our findings suggest that the
link is not simply due to a shared smoking aetiology. This study along with others [3, 21], sug-
gests that structural brain changes can occur in COPD independently of cardiovascular risk.
Hypoxaemia may be a factor, but cognitive impairment has been reported in non-hypoxemic
COPD patients [22] and in our study only seven individuals had mild hypoxia. Episodic noc-
turnal, exertional or exacerbation-related desaturation may have an effect since similar cogni-
tive changes and brain changes have also been reported in sleep apnoea [23, 24], however
cardiovascular disease is also a common comorbidity in that condition and may be an impor-
tant factor.
We found univariate correlations between higher CRP and fibrinogen and WMH volume
and higher CRP and less well organised white matter microstructure, but only the relationship
between CRP and WMH volume remained significant in the multivariable models. CRP is an
acute-phase protein synthesised in response to pro-inflammatory cytokines during infection
and injury. It has been suggested that inflammation provides the link between smoking and
the development of systemic disease [25]. Tobacco smoking promotes a broad range of pulmo-
nary and systemic immune changes [26] and COPD is associated with enhanced inflammatory
responses in the lungs, systemic inflammation and low-level vascular inflammation [27]. Once
established, these inflammatory processes persist beyond smoking cessation [25, 28]. Chronic
systemic inflammation has been associated with greater burden of atherosclerotic disease and
elevated risk of ischaemic stroke within the general population (see review [29]). Other studies
have also reported associations between systemic inflammation, incident brain infarcts, WMH
severity, white matter microstructural abnormalities [30–32] and microcirculatory dysfunc-
tion [33]. Therefore, it is thought that systemic inflammation plays an aetiological role in cere-
bral small vessel disease [30], via endothelial dysfunction, subsequent impairment of blood
flow and increased blood-brain permeability [34]. Our patients were studied in the stable state,
but systemic inflammation may be episodic as COPD exacerbations are associated with
increases in fibrinogen [35] and platelet aggregation [36].
The finding of relationships between blood pressure and MRI markers of brain structure
supports previously reported associations between hypertension and WMHs [37], cerebral
microbleeds [38], brain infarcts [39], white matter microstructural damage [40] and cerebral
atrophy [41]. Prolonged hypertension may lead to accelerated age-related changes in brain
structure and function by promoting small vessel wall remodelling and endothelial dysfunc-
tion leading to compromised autoregulation and leaving the brain vulnerable to hypoperfusion
or hypoxaemia; however, one study reported that cardiovascular risk factors only explained
approximately 2% of WMH variance in older adults [42].
An association was found between lower brain tissue volume and lower CBF, which is con-
sistent with the adverse effects of chronically reduced CBF in neurodegenerative disorders
related to ageing and cardiovascular disease [43]. Reductions in CBF have also been found to
occur in chronic smokers [44], with proposed mechanisms that include smoking-induced oxi-
dative stress, endothelial dysfunction, nitric oxide vasodilatation, neurovascular coupling,
reduction in cardiac output, hypocapnia, and autoregulatory dysfunction [44].
We found no relationships between retinal and kidney microvascular markers and brain
MRI markers. This was unexpected, given that previous studies reported retinal microvascular
changes in chronic smokers and COPD patients [45, 46] and moderate associations between
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retinal markers and features of cerebral small vessel disease (infarcts, cerebral microbleeds and
WMHs), cognitive impairment and dementia (see [47], for a review). It is also possible that
this study was underpowered to detect these effects, since there was missing data for retinal
variables. However, we did find a correlation between higher urine ACR and lower CBF
(r = 0.273, p = 0.027, see online supplement), therefore, it is possible that cerebral hypoperfu-
sion may have mediated at least part of the previously reported relationship between markers
of microvascular disease and changes in brain structure.
Strengths and limitations
This study benefited from a comprehensive range of clinical measures encompassing multiple
end-organs, and high-resolution multi-modal brain MRI. This allowed investigation of a range
of possible relationships between disease markers from different organ systems and the brain.
Despite this, a large amount of variance in the different types of brain marker remained unac-
counted for. A number of factors that might contribute to neurodegeneration in smoking and
COPD were not tested. These include hypercapnia, nocturnal and exertional desaturation, oxi-
dative stress and direct neurotoxic effects from tobacco smoke, including carbon monoxide.
The absence of a healthy control group means that it is not possible to determine whether
the relationships found in this study are specific to smoking-related diseases or are more
widely applicable to the general population. However, the pattern of changes is similar to those
previously reported in the brains of COPD patients compared to healthy controls [3, 21]. Fur-
thermore, white matter hyperintensity lesions are indicative of white matter damage [48]. In
this study, we showed a correlation between the volume of these lesions and well-established
markers of disease such as lung function, breathlessness, blood pressure, troponin and CRP.
We also carried out all analyses after adjusting for age, so it is reasonable to conclude that the
associations that we found are a feature of disease and not an aspect of aging in otherwise
healthy people. The statistical analyses and generalisability of this study were limited by the rel-
atively small sample size (though large compared to similar brain imaging studies in smoking-
related lung disease). The study was designed to test a specific primary hypothesis—that there
are common mediators between COPD and CAD that produce changes in brain structure.
That required a number of tests without correction for multiple comparisons, which increased
the risk of Type-I error and some of the relationships may be spurious, but we used a hierar-
chical statistical approach to reduce this risk as far as possible. Conversely, there was also con-
siderable shared variance between the risk factors identified in this study, which could have led
to over-adjustment in the multiple linear regression analyses and reduced the estimated degree
of association. Structural equation modelling may reduce this bias and provide insight into
causal relationships, but it requires large datasets.
The cross-sectional nature of the comparisons limits the inferences that can be drawn about
causality, particularly the possible influence of treatment. This is exemplified by the case of
lipid lowering drugs such as statins. Several relationships with plasma lipids were the reverse
of what might be expected, probably because lipid lowering treatment was given to patients
with high serum cholesterol. Thus, any analysis of the relationship between treatment and
brain changes could be confounded by treatment indication and treatment duration.
Conclusions
In both COPD and CAD patients, impaired higher blood pressure and raised serum CRP
appear to be independent risk factors for white matter lesion volume. Associations were also
found between lower respiratory function and less organised white matter microstructure and
between higher blood pressure, lower cerebral blood flow and lower brain tissue volumes. A
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large amount of variance in brain structure remained unaccounted, suggesting that other fac-
tors may also contribute. These findings suggest that multiple preventative or therapeutic
interventions may be required to target a range of pathophysiological mechanisms in any
attempts to reduce neurodegeneration and cognitive impairment in people with smoking-
related diseases.
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